Treatment With Namenda in Women at Risk for Cognitive Decline
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This research aims to explore the effectiveness of memantine (Namenda) in treating
post-menopausal women between the ages of 50 and 65, who are at risk for cognitive decline.
Memantine has already been shown to offer cognitive benefits to patients suffering from
Alzheimer's disease, but it's potential for treating those at risk for cognitive decline
without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that
memantine may offer neurocognitive benefits to this population, as well. Participants are
asked to take medication for six months, complete neuropsychological testing, and one blood
draw.